🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

REVEAL GENOMICS' team wishes you joy, peace, and success this holiday season and in the year ahead. #precisiononcology

Announcing a link between B-cell and T-cell immune infiltration and improved survival rates in #breastcancer survivors. These are integrated into #HER2DX and #TNBCDX, enhancing their role in guiding clinical decisions for HER2+ and TNBC. More: ow.ly/Yk5450UFbNw

Moltes gràcies, Barcelona Activa, per convidar-nos a la xerrada "T'acostem a empreses disruptives i innovadores que estan redefinint el mercat laboral", en la qual Ángeles Sebastián, COO, ha parlat dels nous perfils necessaris que ens ajudaran a revolucionar l'#oncologiadeprecisió

💫 Proud to share that we have achieved ISO 27001 Certification! Our CTO, Laia Paré Brunet, remarks: "This certification reinforces our commitment to data security, confidentiality, and integrity at the highest international standards." Huge thanks to our team for making it happen! 🙌🏻

Our work isn’t just about innovation—it’s about impact. We are dedicated to developing cutting-edge diagnostic tools that help define the best therapeutic options for patients with cancer, helping them receive the most effective treatment. #WorldCancerDay #precisiononcology

🚨 ¿Todavía no has escuchado el caso de REVEAL GENOMICS?

💫💫💫

Muchas gracias Círculo Ecuestre y Fundación Fero por ofrecer un espacio para explicar la oncología de precisión de la mano de nuestro CSO y co-founder Aleix Prat #PrecisionOncology en la Charla “Presente y futuro del cáncer” llevada a cabo ayer. ¡Enhorabuena por esta iniciativa!

Today, we honor the incredible contributions of women in every field, every community, and every part of the world. It’s a day to acknowledge progress, recognize challenges, and continue working toward a future built on equality. #IWD #InternationalWomensDay

📢 New study on HER2DX in early-stage HER2+ breast cancer! 🎉 🔹 48% had treatment changes, 73% with reduced therapy. 🔹 Less intense treatment in 69 pCR-high patients matched multi-agent chemo’s pCR rates. 👉🏻esmorwd.org/action/showPdf… 💡#BreastCancer #HER2Positive #Genomics

🗞️ Un estudio coliderado por INCLIVA y el Hospital Clínic-IDIBAPS confirma el impacto clínico de la prueba genómica HER2DX® en el cáncer de mama HER2+ en etapas tempranas 🔗 incliva.es/un-estudio-en-…

HER2DX, a genomic diagnostic test, helped identify patients with early-stage HER2-positive breast cancer with a higher likelihood of achieving a pathological complete response. #bcsm | Olga Martínez-Sáez cancernetwork.com/view/genomic-a…

On another great day for #HER2DX at SGBCC Dr. #MafaldaOliveira from SOLTI #cancerresearch discusses The Definitive Trial , the first prospective #HER2DX trial across 44 hospitals in 7 countries. #SGBCC2025 #breastcancer #precisiononcology

How much does a cancer treatment cost? How does it affect patients and healthcare national systems? ⬇️ ow.ly/3sJZ50VnCB9

🔴 Happening now! Esther Sanfeliu presents the correlation of the #HER2DX genomic test with pathologic features in early-stage HER2+ #breastcancer at USCAP. #HER2DX offers biological insights beyond standard pathology, potentially enhancing personalized treatment.

Moltes gràcies VIA Empresa i a #AnaMariaGonzálezFranco per aquest article en què la nostra cofundadora i CEO Patricia Villagrasa parla dels inicis de la companyia amb el suport de Barcelona Activa, del nostre test #HER2DX, així com del futur que ens espera. ow.ly/TiMS50VpF3Z

Our co-founder & CSO, @prat_aleix on precision oncology at IESE Business School : "We need a 360-degree view with all stakeholders to implement the precision medicine" Thanks, #IESEStudentClub, for an inspiring MBA Healthcare Day 2025!

Com pot la IA ajudar a millorar el diagnòstic del càncer? Patricia Villagrasa de REVEAL GENOMICS i Xavier Dumont de Barcelona Activa comparteixen els seves aplicacions al #RevolucióCatRàdio 3cat.cat/3cat/reveal-ge…

Feliç Dia de Sant Jordi! #SantJordi2025 #HER2DX #precisiononcology #innovation

#ASCO25 | Pre-operative THP leads to pCR in 2/3 of early-stage HER2+ ER- breast cancer patients. Nadine Tung, MD, presents June 2, 3:24–3:36 PM CDT | Hall B1 @EAonc National Cancer Institute The Breast Cancer Research Foundation Susan G. Komen #BCSM #HER2DX REVEAL GENOMICS BIDMC ECOG-ACRIN EA1181 bit.ly/CompassHER2-pC…